The iShares Future Exponential Technologies ETF (XT) seeks to track the Morningstar Exponential Technologies Index, a subset of the Morningstar Global Markets Index composed of developed- and emerging-market companies that produce or use exponential technologies with the potential to displace older models and create new markets. The fund is structured as a passive, diversified index ETF and generally invests at least 80% of its assets in the component securities of its underlying index.
The portfolio holds approximately 220 stocks and manages about $4.0 billion in AUM, with an expense ratio of 0.46%. Its largest positions span both technology and health care: Eli Lilly (LLY), Texas Instruments (TXN), NVIDIA (NVDA), Tesla (TSLA), Microsoft (MSFT), Johnson & Johnson (JNJ), Analog Devices (ADI), Amazon (AMZN), Palo Alto Networks (PANW), and AbbVie (ABBV). Geographically, U.S. companies represent roughly two-thirds of assets, with the remainder spread across Europe and Asia.
By sector, information technology dominates at roughly 45% of assets, followed by health care (about 25%), industrials (about 8%), consumer discretionary (about 7.5%), communication services, utilities, financials, and a small materials sleeve. This balanced technology-and-health-care mix is central to the fund's identity: it captures innovation across semiconductors, software, biotechnology, and pharmaceuticals rather than concentrating in a single industry. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.
XT operates at the intersection of several durable investment themes. In semiconductors, demand for advanced chips tied to artificial intelligence, cloud computing, and electrification has supported a broad set of companies, from U.S. designers to Asian foundries and memory producers. In health care, innovation in obesity and metabolic treatments, oncology, and medical devices continues to reshape the pharmaceutical landscape, with several large-cap drugmakers among the fund's top holdings.
The macroeconomic environment adds a layer of complexity. Because growth-oriented equities carry long-duration cash flows, their valuations are sensitive to interest-rate expectations. Elevated policy rates or shifting inflation data can weigh on the fund's technology and health care growth exposure, even when underlying fundamentals remain intact. Conversely, a more accommodative monetary stance tends to support these long-duration assets. Broader themes such as the energy transition, automation, and digital transformation also influence the fund's industrial and utility holdings.
Over recent weeks and months, XT has traded within a relatively contained range, with price action reflecting the tug-of-war between structural innovation demand and valuation sensitivity to interest rates. The fund declined roughly 5% over the trailing month and a similar magnitude over the most recent quarter, a move consistent with moderate volatility rather than a sharp directional trend.
This behavior is consistent with the portfolio's composition. Semiconductor names such as Texas Instruments, NVIDIA, and Analog Devices are cyclically sensitive and tend to move with demand expectations across computing and industrial markets. Meanwhile, health care leaders including Eli Lilly, Johnson & Johnson, and AbbVie provide a degree of defensive ballast. The fund's diversified, roughly 220-stock structure helps dampen single-stock risk, even as its heavy technology weighting leaves it exposed to broader sector rotation.
Several structural factors are likely to shape XT's performance through 2026. The trajectory of interest rates and inflation remains pivotal, given the fund's meaningful allocation to long-duration growth equities. Semiconductor demand tied to artificial intelligence and data-center buildouts, along with the earnings cycle of major holdings such as NVIDIA, Microsoft, and Texas Instruments, will be a central driver. In health care, pipeline developments and regulatory decisions affecting large pharmaceutical names could move the fund's second-largest sector.
Investors should also monitor capital flows into thematic and technology ETFs, sector rotation between growth and value styles, and policy developments affecting technology and health care. The fund's geographic diversification across developed and emerging markets adds a currency and international-growth dimension. While the diversification across technology and health care provides resilience relative to single-theme funds, the concentration in growth-oriented equities means XT will likely remain sensitive to shifts in the macroeconomic environment and investor sentiment toward innovation-linked assets. From what I see, monitoring these elements closely remains important for positioning decisions.
One tool I find useful for this kind of analysis is Tickeron's AI Screener. It lets me scan thousands of securities with technical indicators, fundamentals, and AI signals to spot shifting sector leadership and potential setups more efficiently than manual methods. This has helped refine my view on funds like XT without overcomplicating the workflow.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 37 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 84%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XT as a result. In 60 of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
XT moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XT crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for XT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for XT's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +4.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where XT advanced for three days, in 254 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
XT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows